Suggested by Bloomberg, blessed by analysts, could an M&A match with a certain MS player be far off for blockbuster-hungry Sanofi?
All the signs are right.
Sanofi CEO Paul Hudson has an M&A war chest set aside from the sale of their Regeneron stock. A few more strategic deals would add considerable excitement to the late-stage pipeline — Job 1 at a pharma giant that long ago drifted to the unimpressive side of Big Pharma and desperately wants out. Bloomberg reports that MS and immune disorders are in the crosshairs at the Paris-based multinational.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily — and it's free.